Viimeisin päivitys :
26/03/2024
Anksiolyytit   Diazepam  
Injektioneste
Oraaliliuos Peräpuikko
Stabilius liuoksessa Stabilius seoksissa Tekijät, jotka vaikuttavat stabiliuteen Yhteensopivuus Antotapa Viitteet Pdf
   Kemiallinen rakenne  

Kauppanimi   Kauppanimi     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Ansiolin Italia
Bamyl Chile
Compaz Brasilia
Daiv Argentiina, Kolumbia
Diactal Argentiina
Diapam Suomi, Turkki
Diazem Turkki
Diazemuls Hollanti, Iso-Britannia, Italia, Kanada
Diazep Saksa
Diazepam Australia, Ecuador, Kanada, Kolumbia, Saksa
Faustan Saksa
Gewalcalm Itävalta
Kiatrium Brasilia
Noan Italia
Normabel Kroatia
Ortopsique Ecuador
Pacitran Marokko
Pax Etelä-Afrikka
Relanium Puola
Rupediz Argentiina
Stedon Kreikka
Stesolid Islanti, Norja, Ruotsi, Saksa, Saudi-Arabia, Sveitsi, Tanska
Sunzepan Meksiko
Tranject Etelä-Afrikka
Valium Belgia, Brasilia, Ecuador, Egypti, Espanja, Etelä-Afrikka, Hollanti, Italia, Itävalta, Kolumbia, Luxemburg, Marokko, Meksiko, Portugali, Ranska, Saksa, Saudi-Arabia, Sveitsi, Venezuela, Yhdistyneet arabiemiirikunnat
Viitteet   Injektioneste   Viitteet : Diazepam  
Tyyppi Julkaisu
55 Lehti Smith A, Bird G.
The compatibility of diazepam with infusion fluids and their containers.
J Clin Hosp Pharm 1982 ; 7: 181-186.
58 Lehti Parker WA.
Physical compatibility of ranitidine HCl with preoperative injectable medications.
Can J Hosp Pharm 1985 ; 38: 160-161.
59 Lehti Trissel LA, Gilbert DL, Martinez JF, Kim MC.
Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
73 Lehti Lor E, Takagi J.
Visual compatibility of foscarnet with other injectable drugs.
Am J Hosp Pharm 1990 ; 47: 157-159.
93 Lehti Hutchings SR, Rusho WJ, Tyler LS.
Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery.
Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
190 Lehti Lee MG.
Sorption of four drugs to polyvinyl chloride and polybutadiene intravenous administration sets.
Am J Hosp Pharm 1986 ; 43: 1945-1950.
198 Lehti Gayed AA, Kheshary PR, Hinkle RL.
Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.
Am J Health-Syst Pharm 1995 ; 52: 516-520.
226 Lehti Walker SE, DeAngelis C, Iazzetta J.
Stability and compatibility of combinations of hydromorphone and a second drug.
Can J Hosp Pharm 1991 ; 44: 289-295.
266 Lehti Patel PR.
Compatibility of meropenem with commonly used injectable drugs.
Am J Health-Syst Pharm 1996 ; 53: 2853-2855.
299 Lehti Trissel LA, Martinez JF, Gilbert DL.
Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300 Lehti Trissel LA, Gilbert DL, Martinez JF.
Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
348 Lehti Hancock BG, Black CD.
Effect of a polyethylene-lined administration set on the avaibility of diazepam injection.
Am J Hosp Pharm 1985 ; 42: 335-339.
350 Lehti Martens HJ, De Goede PN, Van Loenen AC.
Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers.
Am J Hosp Pharm 1990 ; 47: 369-373.
351 Lehti Yliruusi JK, Uotila JA, Kristoffersson ER.
Effect of flow rate and type of IV container on adsorption of diazepam to IV administration systems.
Am J Hosp Pharm 1986 ; 43: 2795-2799.
352 Lehti Yliruusi JK, Uotilo JA, Kristoffersson ER.
Effect of tubing length on adsorption of diazepam to polyvinyl chloride administration sets.
Am J Hosp Pharm 1986 ; 43: 2789-2794.
402 Lehti Savitsky ME.
Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection.
Am J Hosp Pharm 1990 ; 47: 820-821.
476 Lehti Knapp AJ, Mauro VF, Alexander KS.
Incompatibility of ketorolac tromethamine with selected postoperative drugs.
Am J Hosp Pharm 1992 ; 49: 2960-2962.
496 Lehti Lor E, Sheybani T, Takagi J.
Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.
Am J Hosp Pharm 1991 ; 48: 744-746.
616 Lehti Jump WG, Plaza VM, Poremba A.
Compatibility of nalbuphine hydrochloride with other preoperative medications.
Am J Hosp Pharm 1982 ; 39: 841-843.
621 Lehti Yliruusi JK, Sothmann AG, Laine RH, Rajasilta RA, Kristoffersson ER.
Sorptive loss of diazepam and nitroglycerin from solutions to three types of containers.
Am J Hosp Pharm 1982 ; 39: 1018-1021.
660 Lehti Michaels MR, Stauffer GL, Haas DP.
Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility.
Ann Pharmacotherapy 1996 ; 30: 228-232.
711 Lehti Cloyd JC, Vezeau C, Miller KW.
Avaibility of diazepam from plastic containers.
Am J Hosp Pharm 1980 ; 37: 492-496.
712 Lehti Parker WA, MacCara ME.
Compatibility of diazepam with intravenous fluid containers and administration sets.
Am J Hosp Pharm 1980 ; 37: 496-500.
730 Lehti Allen LV, Saul Levinson R, Phisutsinthop D.
Compatibility of various admixtures with secondary additives at Y-injection site of intravenous administration sets.
Am J Hosp Pharm 1977 ; 34: 939-943.
731 Lehti Morris ME.
Compatibility and stability of diazepam injection following dilution with intravenous fluids.
Am J Hosp Pharm 1978 ; 35: 669-672.
921 Lehti Trissel LA, Gilbert DL, Martinez JF.
Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration.
Hosp Pharm 1998 ; 33: 284-292.
939 Lehti Gilbar PJ, Groves CF.
Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.
Aust J Hosp Pharm 1994 ; 24: 167-170.
1041 Lehti Hasegawa GR, Eder JF.
Visual compatibility of dobutamine hydrochloride with other injectable drugs.
Am J Hosp Pharm 1984 ; 41: 949-951.
1057 Lehti Cutie MR.
Compatibility of verapamil hydrochloride injection with commonly used additives.
Am J Hosp Pharm 1983 ; 40: 1205-1207.
1067 Lehti Zeidler C, Dettmering D, Schrammel W, Spieteller M.
Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers.
EJHP 1999 ; 5: 106-110.
1102 Lehti Cossum PA, Roberts MS.
Availability of isosorbide dinitrate, diazepam and chlormethiazole, from i.v. delivery systems.
Eur J Clin Pharmacol 1981 ; 19: 181-185.
1173 Lehti Kowaluk EA, Roberts MS, Blackburn HD, Polack AE.
Interactions between drugs and polyvinyl chloride infusion bags.
Am J Hosp Pharm 1981 ; 38: 1308-1314.
1182 Lehti Mason NA, Cline S, Hyneck ML, Berardi RR, Ho NFH, Flynn GL.
Factors affecting diazepam infusion: solubility, administration-set composition, and flow rate.
Am J Hosp Pharm 1981 ; 38: 1449-1454.
1199 Lehti Smith FM, Nuessle NO.
Stability of diazepam injection repackaged in glass unit-dose syringes.
Am J Hosp Pharm 1982 ; 1687-1690.
1200 Lehti Chaudry IA, Bruey KP, Hurlburt LE, Oden EM.
Compatibility of netilmycin sulfate injection with commonly used intravenous injections and additives.
Am J Hosp Pharm 1981 ; 38: 1737-1742.
1232 Lehti Beatson C, Taylor A.
A physical compatibility study of furosemide & flucloxacillin injections.
Br J Pharm Pract 1987 ; 9: 223-226, 236.
1269 Lehti DeMuynck C, De Vroe C, Remon JP, Colardyn F.
Binding of drugs to end-line filters: a study of four commonly administered drugs in intensive care units.
J Clin Pharm Ther 1988 ; 13: 335-340.
1271 Lehti Mathot F, Bonnard J, Paris P, Bosly J.
Reliable continuous IV perfusion system for diazepam.
J Pharm Belg 1982 ; 37: 153-156.
1366 Lehti Jeglum EL, Winter E, Kotos M.
Nafcillin sodium incompatibility with acidic solutions.
Am J Hosp Pharm 1981 ; 38: 462,464.
1424 Lehti Gottwald MD, Akerd LC, Liu PK, Orsulak PJ, Corry M, Bacchetti P, Fields SM, Loxenstein DH, Alldredge BK.
Prehospital stability of diazepam and lorazepam.
Am J Emerg Med 1999 ; 17: 333-337.
1438 Lehti Souney PF, Solomon MA, Stancher D.
Visual compatibility of cimetidine hydrochloride wih common preoperative injectable medications.
Am J Hosp Pharm 1984 ; 41: 1840-1841.
1472 Lehti Salomies HEM, Heinonen RM, Toppila MAI.
Sorptive loss of diazepam, nitroglycerin and warfarin sodium to polypropylene-lined infusion bags (Softbags).
Int J Pharm 1994 ; 110: 197-201.
1512 Laboratorio Tirofiban (Aggrastat®) - Summary of Product Characteristics
Beacon Pharmaceuticals Ltd 2015
1522 Laboratorio Macoflex N®
Maco Pharma 2001
1603 Lehti Bergquist PA, Manas D, Hunke WA, Reed RA.
Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs.
Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1625 Lehti Trissel LA, Saenz C, Williams YW, Ingram D.
Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.
Int J Pharm Compound 2001 ; 5: 314-321.
1662 Lehti Trissel LA, Saenz CA, Ingram DS, Ogundele AB.
Compatibility screening of oxaliplatin during simulated Y-site administration with other drugs.
J Oncol Pharm Practice 2002 ; 8: 33-37.
1712 Lehti Trissel LA, Saenz CA.
Compatibility screening of Precedex during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 230-233.
1713 Lehti Trissel LA, Saenz CA.
Compatibility screening of bivalirudin during simulated Y-site administration with other drugs.
Int J Pharm Compound 2002 ; 6: 311-315.
1721 Lehti Trissel LA, Williams KY, Baker MB.
Compatibility screening of Hextend during simulated Y-site administration with other drugs.
Int J Pharm Compound 2001 ; 5: 69-72.
1803 Lehti Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB.
Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925 Lehti Trissel LA , Williams KY, Gilbert DL.
Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions.
J Am Pharm Assoc 2000 ; 40: 515-519.
1960 Lehti Kambia NK, Dine T, Dupin-Spriet T, Gressier B, Luycks M, Goudaliez F, Brunet C.
Compatibility of nitroglycerin, diazepam and chlorpromazine with a new multilayer material for infusion containers.
J Pharm Biomed Anal 2005 ; 37: 259-264.
1974 Lehti Chandler SW, Trissel LA, Weinstein SM
Combined administration of opoids with selected drugs to manage pain and other cancer symptoms initial safety screening for compatibility.
J Pain Symptom Manage 1996 ; 12, 3: 168-171.
2087 Lehti Ferreira E, Forest JM, Hildgen P.
Compatibility of dimenhydrinate injectable by Y administration.
Pharmactuel 2004 ; 37: 17-20.
2090 Lehti Pere H, Chasse V, Forest JM, Hildgen P.
Compatibility of injectable pantoprazole in Y-site administration.
Pharmactuel 2004 ; 37: 193-196.
2262 Lehti Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D.
Compatibility of doripenem with other drugs during simulated Y-site administratioN
Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269 Lehti Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H.
Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2324 Lehti Treleano A, Wolz G, Brandsch R, Welle F.
Investigation into the sorption of nitroglycerin and diazepam into PVC tubes and alternative tube materials during application
Int J Pharm 2009 ; 369, 1-2 : 30-37
3012 Lehti Sullivan T, Forrest J.M, Leclair G.
Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration
Hosp Pharm 2015 ; 50, 3: 214-220.
3184 Laboratorio
Hyaluronidase (Hyalase®) - Summary of Product characteristics.
CP Pharmaceuticals 2005
3216 Lehti Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G.
Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y.
Pharmactuel 2011 ; 44, 1 : 14-18
3249 Lehti Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB.
Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3332 Laboratorio Tigecycline (Tigacyl®) - Summary of Product characteristics
Pfizer 2012
3408 Lehti Tollec S, Touzin K, Pelletier E, Forest J.M.
Evaluation visuelle de la compatibilité physique de la naloxone avec d’autres médicaments intraveineux usuels.
Pharmactuel 2013 ; 46, 1 : 16-21.
3474 Laboratorio Fluorouracil - Summary of Product Characteristics
Accord Healthcare Limited 2009
3501 Laboratorio Ketamine hydrochloride (Ketalar®) - Summary of Product Characteristics
Pfizer 2011
3521 Laboratorio Tramadol® - Summary of Product Characteristics.
Beacon Pharmaceuticals 2012
3539 Laboratorio Bivalirudin (Angiox®) - Summary of Product Characteristics.
The Medecines Company 2013
3540 Laboratorio Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3560 Laboratorio Linezolid (Zyvox®) - Summary of Product Characteristics
Pharmacia 2013
3564 Laboratorio Rocuronium B Braun - Résumé des caractéristiques du produit.
B Braun 2012
3571 Lehti Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M.
Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration.
Hosp Pharm 2014 ; 49, 1: 42-47.
3599 Laboratorio Glycopyrrolate Injection U.S.P. - Summary of Product Characteristics
Amco Amdipharm Mercry 2013
3607 Laboratorio Esmolol hydrochloride for injection - Summary of Product Characteristics
AOP Orphan Pharmaceuticals AG 2013
3614 Laboratorio Nicardipine Injection - Summary of Product Characteristics
American Regent Inc 2013
3617 Laboratorio Hyaluronidase (Hyalase®) - Summary of Product Characteristics
Wockhardt 2011
3672 Laboratorio Nalbuphine Mylan - Résumé des caractéristiques du produit
Mylan SAS 2016
3766 Lehti Forrest J.M, Hildgen P.
Compatibilité de l’acétylcystéine injectable lors de son administration en Y avec d’autres médicaments usuels
Pharmactuel 2014 ; 47, 3 : 161-165.
3767 Lehti Legris M.E, Lavoie A, Forrest J.M, Hildgen P.
Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels.
Pharmactuel 2014 ; 47, 3 : 167-172.
3824 Lehti Boudi S, Roy H, Forest JM, Leclair G.
Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y.
Pharmactuel 2023 2023;56,3:91-98
3885 Lehti Su-Eon Jin, Siwon You, Seungho Jeon, Sung-Joo Hwang.
Diazepam sorption to PVC- and non-PVC-based tubes in administration sets with quantitative determination using a high-performance liquid chromatographic method.
Int J Pharm 2016 ; 506 : 414-419.
3932 Laboratorio Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit
Serb Laboratoire 2015
3941 Laboratorio Nicardipine - Summary of Product Characteristics
Concordia International 2017
3964 Lehti Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G.
Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments.
Pharmactuel 2017 ; 50,1 : 27-33.
4154 Laboratorio Bleomycin sulfate- Summary of Product Characteristics
Accord Health Care 2018
4319 Lehti Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.
Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.
Hosp Pharm 2020 ; 55, 5: 332-337.
4428 Lehti Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J.
Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma.
J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132.
4435 Lehti Hanifah S, Nugroho B.H, Chabib L.
Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection.
Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27.
4603 Lehti Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G.
Compatibility of Lactated Ringer’s Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration.
Hosp Pharm 2021 ; 56, 4: 228-234.
4650 Laboratorio Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021.
Advanz Pharma 2021
4700 Laboratorio Esketamine 25 mg/mL solution for injection/infusion. - Summary of Product Characteristics
AS Kalceks 2022
4742 Lehti Macoviciuc M, Nguyen C, Forest J-M, Leclair G.
Compatibilité physique de l’acétaminophène injectable avec 102 autres médicaments lors d’une administration en Y.
Pharmactuel 2022 ; 55, 4: 247-255.

  Mentions Légales